E P Figueiredo1, J M Ribeiro1, E K Nishio1, S Scandorieiro1, A F Costa2, V F Cardozo1, A G Oliveira1, N Durán2,3,4, L A Panagio1, Rkt Kobayashi1, G Nakazato1. 1. Department of Microbiology, Center of Biological Sciences, Universidade Estadual de Londrina, Londrina, Paraná, Brazil. 2. NanoBioss, Institute of Chemistry, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. 3. Institute of Chemistry, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil. 4. LNNano (National Laboratory of Nanotecnology), CNPEM, Campinas, São Paulo, Brazil.
Abstract
BACKGROUND: Multidrug-resistant bacteria such as extended-spectrum beta-lactamase (ESBL), Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus (MRSA) pose a challenge to the human health care system. MRSA is among the major causes of hospital-acquired and community infections. METHODS: Therefore, in the present study, we evaluated the antibacterial activity of silver nanoparticles synthesized by Fusarium oxysporum (AgNPbio) in combination with simvastatin against reference and multidrug-resistant bacterial strains. RESULTS: Simvastatin showed a minimal inhibitory concentration (MIC) ranging from 0.062 to 0.25 mg mL-1 against MRSA. AgNPbio with a size of 77.68± 33.95 nm and zeta potential -34.6 ± 12.7 mV showed an MIC of 0.212 mg mL-1 against S. aureus including MRSA strains. The checkerboard assay and time-kill curves exhibited a synergistic effect of the simvastatin-AgNPbio combination on antibacterial activity against MRSA strains. The combination of simvastatin and AgNPbio demonstrated antibacterial activity against Escherichia coli producing ESBL. Scanning electron microscopy showed the formation of cell surface protrusions after treatment with AgNPbio and the formation of a large amorphous mass after treatment with simvastatin, both in MRSA. CONCLUSION: Our results indicate that the combination of AgNPbio and simvastatin could be a great future alternative in the control of bacterial infections, where, when combined with simvastatin, smaller doses of AgNPbio are required, with the same antibacterial activity.
BACKGROUND: Multidrug-resistant bacteria such as extended-spectrum beta-lactamase (ESBL), Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus (MRSA) pose a challenge to the human health care system. MRSA is among the major causes of hospital-acquired and community infections. METHODS: Therefore, in the present study, we evaluated the antibacterial activity of silver nanoparticles synthesized by Fusarium oxysporum (AgNPbio) in combination with simvastatin against reference and multidrug-resistant bacterial strains. RESULTS: Simvastatin showed a minimal inhibitory concentration (MIC) ranging from 0.062 to 0.25 mg mL-1 against MRSA. AgNPbio with a size of 77.68± 33.95 nm and zeta potential -34.6 ± 12.7 mV showed an MIC of 0.212 mg mL-1 against S. aureus including MRSA strains. The checkerboard assay and time-kill curves exhibited a synergistic effect of the simvastatin-AgNPbio combination on antibacterial activity against MRSA strains. The combination of simvastatin and AgNPbio demonstrated antibacterial activity against Escherichia coli producing ESBL. Scanning electron microscopy showed the formation of cell surface protrusions after treatment with AgNPbio and the formation of a large amorphous mass after treatment with simvastatin, both in MRSA. CONCLUSION: Our results indicate that the combination of AgNPbio and simvastatin could be a great future alternative in the control of bacterial infections, where, when combined with simvastatin, smaller doses of AgNPbio are required, with the same antibacterial activity.
Authors: Jose Ruben Morones; Jose Luis Elechiguerra; Alejandra Camacho; Katherine Holt; Juan B Kouri; Jose Tapia Ramírez; Miguel Jose Yacaman Journal: Nanotechnology Date: 2005-08-26 Impact factor: 3.874
Authors: Jun Sung Kim; Eunye Kuk; Kyeong Nam Yu; Jong-Ho Kim; Sung Jin Park; Hu Jang Lee; So Hyun Kim; Young Kyung Park; Yong Ho Park; Cheol-Yong Hwang; Yong-Kwon Kim; Yoon-Sik Lee; Dae Hong Jeong; Myung-Haing Cho Journal: Nanomedicine Date: 2007-03 Impact factor: 5.307
Authors: Nelson Durán; Priscyla D Marcato; Oswaldo L Alves; Gabriel I H De Souza; Elisa Esposito Journal: J Nanobiotechnology Date: 2005-07-13 Impact factor: 10.435
Authors: Sara Scandorieiro; Bianca C D Rodrigues; Erick K Nishio; Luciano A Panagio; Admilton G de Oliveira; Nelson Durán; Gerson Nakazato; Renata K T Kobayashi Journal: Front Microbiol Date: 2022-05-06 Impact factor: 6.064
Authors: Elena Sánchez-López; Daniela Gomes; Gerard Esteruelas; Lorena Bonilla; Ana Laura Lopez-Machado; Ruth Galindo; Amanda Cano; Marta Espina; Miren Ettcheto; Antoni Camins; Amélia M Silva; Alessandra Durazzo; Antonello Santini; Maria L Garcia; Eliana B Souto Journal: Nanomaterials (Basel) Date: 2020-02-09 Impact factor: 5.076
Authors: Alexia Barbarossa; Antonio Rosato; Filomena Corbo; Maria Lisa Clodoveo; Giuseppe Fracchiolla; Antonio Carrieri; Alessia Carocci Journal: Antibiotics (Basel) Date: 2022-06-17